UMIN-CTR History
Name： UMIN ID：
| Unique ID issued by UMIN | UMIN000030206 |
|---|---|
| Receipt number | R000034306 |
| Scientific Title | Randomized phase II study of osimertinib plus bevacizumab and osimertinib for chemotherapy-naive patients with nonsquamous non-small cell lung cancer harboring EGFR mutations (investigator-initiated multicenter clinical trial, WJOG9717L) |
| Date of disclosure of the study information | 2017/12/01 |
| Last modified on | 2023/07/26 11:09:54 |
| No. | Disposal | Last modified on | Item of update | |
|---|---|---|---|---|
| 1 | Insert | 2017/12/01 09:41:54 | ||
| 2 | Update | 2017/12/01 09:46:37 | Public title |
|
| 3 | Update | 2018/06/03 12:33:29 | Anticipated trial start date |
|
| 4 | Update | 2018/06/04 09:09:29 | Recruitment status |
|
| 5 | Update | 2018/10/29 11:22:32 | Recruitment status |
|
| 6 | Update | 2020/12/02 13:18:57 | Date of IRB Last follow-up date Date of closure to data entry Date trial data considered complete Date analysis concluded |
|
| 7 | Update | 2020/12/02 13:24:29 | 1st name of lead principal investigator Last name of lead principal investigator 1st name of lead principal investigator Last name of lead principal investigator Zip code Address Last name of contact person Last name of contact person Zip code Address Co-sponsor Organization Organization Address Address Tel |
|
| 8 | Update | 2021/12/03 13:22:45 | Date of closure to data entry Date trial data considered complete Date analysis concluded |
|
| 9 | Update | 2022/10/13 12:35:27 | Recruitment status Date analysis concluded |
|
| 10 | Update | 2023/07/26 11:09:54 | URL releasing protocol Publication of results URL related to results and publications Number of participants that the trial has enrolled Results Results Results date posted Date of the first journal publication of results Baseline Characteristics Baseline Characteristics Participant flow Participant flow Adverse events Adverse events Outcome measures Outcome measures |
